SSG
GDTC icon

Summit Securities Group’s CytoMed Therapeutics GDTC Stock Holding History

Summit Securities Group’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,407
Closed -$19K – 758
2023
Q3 		$19K Buy
+5,407
New +$20.4K ﹤0.01% 367

Other funds holding GDTC

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Summit Securities Group's GDTC Position: Q4 2023 in Review

Summit Securities Group sold out of CytoMed Therapeutics (GDTC) in Q4 2023, closing a stake of 5,407 shares — an estimated $19K sold.

Summit Securities Group first reported a position in GDTC in Q3 2023 and held it in 1 quarter. The position peaked at $19K in Q3 2023. 2 funds tracked by Wall St. Rank hold GDTC as of Q4 2023.

  • Summit Securities Group reported no remaining CytoMed Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Summit Securities Group sold 5,407 CytoMed Therapeutics shares in Q4 2023, an estimated $19K.
  • Summit Securities Group first reported a position in CytoMed Therapeutics in Q3 2023 and held it in 1 quarter.
  • Summit Securities Group's CytoMed Therapeutics position peaked at $19K in Q3 2023.
  • 2 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q4 2023.

Based on Summit Securities Group's 13F filing for Q4 2023, filed 14 Feb 2024.